Latest news with #MolecularPartners
Yahoo
19-05-2025
- Business
- Yahoo
Molecular Partners to Present at Upcoming Investor Conferences
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ('Molecular Partners' or the 'Company'), today announced that members of the management team will participate in two upcoming investor conferences. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET TD Cowen's 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA: Fireside chat on Wednesday, May 28, 2025 beginning at 10:00am ET Both events will be webcast and available on the Molecular Partners website, under the investors tab. About Molecular Partners AG Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN) is a clinical-stage biotech company pioneering the design and development of DARPin therapeutics for medical challenges other drug modalities cannot readily address. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. Molecular Partners leverages the advantages of DARPins to provide unique solutions to patients through its proprietary programs as well as through partnerships with leading pharmaceutical companies. Molecular Partners was founded in 2004 and has offices in both Zurich, Switzerland and Concord, MA, USA. For more information, visit and find us on LinkedIn and Twitter / X @MolecularPrtnrs For further details, please contact:Seth Lewis, SVP Investor Relations & StrategyConcord, Massachusetts, +1 781 420 2361 Laura Jeanbart, PhD, Head of Portfolio Management & CommunicationsZurich-Schlieren, +41 44 575 19 35
Yahoo
06-04-2025
- Business
- Yahoo
Hedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year losses
Significantly high institutional ownership implies Molecular Partners' stock price is sensitive to their trading actions A total of 3 investors have a majority stake in the company with 50% ownership Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. If you want to know who really controls Molecular Partners AG (VTX:MOLN), then you'll have to look at the makeup of its share registry. And the group that holds the biggest piece of the pie are hedge funds with 50% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). As a result, hedge funds investors endured the highest losses last week after market cap fell by CHF21m. Needless to say, the recent loss which further adds to the one-year loss to shareholders of 11% might not go down well especially with this category of shareholders. Hedge funds typically use aggressive strategies that focus on short-term gains. Because of their large stake in Molecular Partners, they hold a lot of power, and persistent under performance could lead to them influencing management decisions that might diverge from the company's long-term goals. Let's delve deeper into each type of owner of Molecular Partners, beginning with the chart below. View our latest analysis for Molecular Partners Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing. We can see that Molecular Partners does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Molecular Partners' earnings history below. Of course, the future is what really matters. It looks like hedge funds own 50% of Molecular Partners shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. BVF Partners L.P. is currently the company's largest shareholder with 27% of shares outstanding. With 18% and 5.6% of the shares outstanding respectively, Suvretta Capital Management, LLC and EcoR1 Capital, LLC are the second and third largest shareholders. In addition, we found that Patrick Amstutz, the CEO has 2.0% of the shares allocated to their name. A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 50% stake. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it. Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. Shareholders would probably be interested to learn that insiders own shares in Molecular Partners AG. In their own names, insiders own CHF5.2m worth of stock in the CHF117m company. This shows at least some alignment, but we usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling. The general public-- including retail investors -- own 28% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Public companies currently own 4.7% of Molecular Partners stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. It's always worth thinking about the different groups who own shares in a company. But to understand Molecular Partners better, we need to consider many other factors. For instance, we've identified 3 warning signs for Molecular Partners (1 shouldn't be ignored) that you should be aware of. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future . NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
09-03-2025
- Business
- Yahoo
Molecular Partners Full Year 2024 Earnings: CHF1.59 loss per share (vs CHF1.89 loss in FY 2023)
Net loss: CHF54.0m (loss narrowed by 13% from FY 2023). CHF1.59 loss per share (improved from CHF1.89 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 58% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Europe. Performance of the market in Switzerland. The company's shares are down 4.8% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Molecular Partners (at least 2 which shouldn't be ignored), and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
